Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Incannex persists with CBD, hydroxychloroquine COVID drug
Health & Biotech
Health: Immutep has dosed the last patient in one of its cancer studies
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Experts
Scopo’s health powerplays: Clinical trials are back
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Even bacteria fighter Next Science is feeling the coronavirus pinch
Health & Biotech
Health: Neuren’s mice are happily burying marbles after PMS neurotherapy
Health & Biotech
Health: Neuren gets extra FDA push for its treatment for rare Rett disease
Health & Biotech
Christmas may have come early for Biotron and its HIV cure
Health & Biotech
Biotech exec pay — are they delivering returns that equal their pay packets?
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
The life sciences investment wave is building. Here’s how to ride it.
Health & Biotech
Health: Roots’ cannabis-cooling tech might help boost crop yields by up to 118%
Health & Biotech
